HIV maturation inhibitor BMS-955176 looks promising in early study
Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up
Doravirine works as well as efavirenz with fewer CNS side-effects
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine
Novel techniques probed in cure research
Therapy with newer, safer antiretrovirals an option for the majority of HIV-positive patients
Investigational protease inhibitor TMC310911 highly potent in phase 2 study
New NNRTI doravirine matches efavirenz for first-line HIV treatment
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation
